In the pharmaceutical industry, the process of developing nascent drugs to cure a disease is quite long, costly, and at the same time uncertain. In light of this, many experts in this space cite that the costs of developing new drugs can be reduced by the use of new technologies and with a deep understanding of biology. Albeit the objectives of drug delivery remain the same, the methods and techniques used in drug development continue to experience radical changes. In a nutshell, the standard approach to drug discovery is to identify a single molecular disease target and subsequently identify a compound that interacts and modulates with high specificity. Today, majority of the innovation reinvigorating the drug development methodologies seeks to access and integrate more information – about targets, compounds, and disease phenotypes. Next, the increasing size of chemical libraries and high throughput screening (HTS) technologies have enabled thousands or millions of compounds to be screened and the concomitant increase in compounds have supplemented the urgency for the bioanalysis of metabolites, and a need for faster turnaround.
To assist CIOs maneuver in the right direction while working on Drug Discovery and Development, a distinguished panel of CEOs, CIOs, VCs, and analysts along with the Pharma Tech Outlook’s editorial board has selected the leading Drug Discovery and Development service providers in Europe. The companies featured in this edition demonstrate an ability to develop innovative technologies combined with outstanding customer service.
We present to you Top 10 Drug Discovery and Development Consulting/Services Companies in Europe - 2019.
